Apricus Biosciences (APRI) Tops Q3 EPS by 2c

Apricus Biosciences (NASDAQ: APRI) reported Q3 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.23 million.

For earnings history and earnings-related data on Apricus Biosciences (APRI) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Analog Devices (ADI) Reiterated at Overweight by Cantor Fitzgerald: Beat and Raise Expected
• Evaxion adds brain cancer vaccine program, drops EVX-03